In contrast, treatment with the Cx43 inhibitor, 18β-glycyrrhetinic acid, inhibits the effect of PKC on mitochondrial dysfunction indicating that PKC-mediated Cx43 S368 phosphorylation is essential to reduce mitochondrial dysfunction in dilated cardiomyopathy and therefore could serve as a novel therapeutic target for cardiomyopathy (197). The gene discussed is GJA1; the disease is cardiomyopathy.